MDT

95.78

-0.22%↓

VEEV

290.05

+1.59%↑

A

146.21

+2.28%↑

HQY

96.27

+3.61%↑

TLRY

1.48

-5.73%↓

MDT

95.78

-0.22%↓

VEEV

290.05

+1.59%↑

A

146.21

+2.28%↑

HQY

96.27

+3.61%↑

TLRY

1.48

-5.73%↓

MDT

95.78

-0.22%↓

VEEV

290.05

+1.59%↑

A

146.21

+2.28%↑

HQY

96.27

+3.61%↑

TLRY

1.48

-5.73%↓

MDT

95.78

-0.22%↓

VEEV

290.05

+1.59%↑

A

146.21

+2.28%↑

HQY

96.27

+3.61%↑

TLRY

1.48

-5.73%↓

MDT

95.78

-0.22%↓

VEEV

290.05

+1.59%↑

A

146.21

+2.28%↑

HQY

96.27

+3.61%↑

TLRY

1.48

-5.73%↓

Search

Krystal Biotech Inc

Open

BrancheGesundheitswesen

189.68 -2.2

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

189.15

Max

195.95

Schlüsselkennzahlen

By Trading Economics

Einkommen

2.6M

38M

Verkäufe

7.9M

96M

KGV

Branchendurchschnitt

37.625

36.442

Gewinnspanne

39.914

Angestellte

275

EBITDA

1.5M

39M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+8.41% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

3. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

1.4B

5.3B

Vorheriger Eröffnungskurs

191.88

Vorheriger Schlusskurs

189.68

Nachrichtenstimmung

By Acuity

30%

70%

77 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Krystal Biotech Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

20. Okt. 2025, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for Takaichi's Policy Steps -- Market Talk

20. Okt. 2025, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

20. Okt. 2025, 23:36 UTC

Market Talk

Gold Edges Higher on Likely Dip-Buying Interest -- Market Talk

20. Okt. 2025, 22:14 UTC

Market Talk

Zions Management Confident $50M Charge Was Isolated Event -- Market Talk

20. Okt. 2025, 22:00 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Berkshire May Have Left $50 Billion on Table. Apple Stock Hit a Record. -- Barrons.com

20. Okt. 2025, 21:49 UTC

Akquisitionen, Fusionen, Übernahmen

Kering Sells Beauty Business to L'Oréal. Everyone but This Company Wins. -- Barrons.com

20. Okt. 2025, 20:56 UTC

Akquisitionen, Fusionen, Übernahmen

These Stocks Moved the Most Today: Apple, Amazon, TSMC, Cleveland-Cliffs, Super Micro, Cooper Cos., Tesla, Netflix, and More -- Barrons.com

20. Okt. 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

20. Okt. 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

20. Okt. 2025, 20:38 UTC

Ergebnisse

Steel Dynamics: Encouraging Demand Drivers of Manufacturing Onshoring, Infrastructure Program Funding, Lower Interest Rates, Increasing Regionalization of Supply Chains in U.S. >STLD

20. Okt. 2025, 20:38 UTC

Ergebnisse

Steel Dynamics: Expect to Benefit From Stronger Demand Across Platforms, Including Aluminum Flat Rolled Products, as We Move Into 2026 >STLD

20. Okt. 2025, 20:38 UTC

Ergebnisse

Steel Dynamics: Some Order Hesitancy From Flat Rolled Steel Customers Due to Domestic Trade Actions >STLD

20. Okt. 2025, 20:36 UTC

Ergebnisse

Steel Dynamics: Continue to Observe Some Customer Inventory Overhang of Value-Added Flat Rolled Products That Were Imported Earlier This Yr >STLD

20. Okt. 2025, 20:36 UTC

Ergebnisse

Steel Dynamics: View U.S. Intl Trade Commission's Final Determinations on Coated Flat Rolled Steel as a Significant Positive Development >STLD

20. Okt. 2025, 20:36 UTC

Ergebnisse

Steel Dynamics: Discussions With Customers Reinforce the Increasing Importance of Low-Carbon, U.S.-Made Steel and Aluminum, Positioning Our Businesses for a Long-Term Competitive Advantage >STLD

20. Okt. 2025, 20:36 UTC

Ergebnisse

Steel Dynamics: Improving Market Conditions, Including Increased Trade Stability and Favorable Interest Rate Environment, Will Contribute to Strong Domestic Demand for Steel and Aluminum >STLD

20. Okt. 2025, 20:16 UTC

Market Talk

Canada Labor-Market Indicators Lean Dovish -- Market Talk

20. Okt. 2025, 20:05 UTC

Ergebnisse

GE Aerospace Earnings Are on Tap. After the Turnaround, Investors Wonder What's Next. -- Barrons.com

20. Okt. 2025, 19:39 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Industrials Post Positive Earnings. 3 Stocks Whose Charts Say 'Buy.' -- Barrons.com

20. Okt. 2025, 19:34 UTC

Market Talk

U.S. Natural Gas Futures Jump on Colder Weather Outlook -- Market Talk

20. Okt. 2025, 19:32 UTC

Market Talk

Oil Futures Extend Losses on Oversupply Concerns -- Market Talk

20. Okt. 2025, 19:00 UTC

Akquisitionen, Fusionen, Übernahmen

These Stocks Are Moving the Most Today: Apple, Amazon, TSMC, Cleveland-Cliffs, Super Micro, Cooper Cos., Tesla, Netflix, and More -- Barrons.com

20. Okt. 2025, 18:29 UTC

Market Talk

Apple Sitting on Best Long-Term Product Roadmap in Years -- Market Talk

20. Okt. 2025, 18:11 UTC

Market Talk

Economic Vital Signs Missing in Bank of Canada Survey -- Market Talk

20. Okt. 2025, 18:04 UTC

Market Talk

Uncertainty Remains Top Concern Among Canada Firms -- Market Talk

20. Okt. 2025, 17:03 UTC

Market Talk

Weak Demand Signals Narrower Profit Margins For Canada Firms -- Market Talk

20. Okt. 2025, 17:01 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20. Okt. 2025, 17:01 UTC

Market Talk

Bank of Canada Surveys Present Shaky Economic Outlook -- Market Talk

20. Okt. 2025, 16:43 UTC

Market Talk

Canada Public-Sector Workers Fret Most On Labor-Market Weakness -- Market Talk

20. Okt. 2025, 16:25 UTC

Market Talk

U.S. Natural Gas Extends Rebound on Weather Outlook -- Market Talk

Peer-Vergleich

Kursveränderung

Krystal Biotech Inc Prognose

Kursziel

By TipRanks

8.41% Vorteil

12-Monats-Prognose

Durchschnitt 212.44 USD  8.41%

Hoch 255 USD

Tief 166 USD

Basierend auf 10 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Krystal Biotech Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

10 ratings

9

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

133.221 / 169.73Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Strong Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

77 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
help-icon Live chat